Program
MWN105
A development code. Also written as “MWN105 1”, “MWN105 2” and “MWN105 3”.
Its studies are mostly in Obesity, led by Lepu Medical.
Furthest: phase 2, since Sep 1, 20263 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lepu Medical | 31 open or running | phase 2since Sep 1, 2026 | Aug 31, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2026First study: phase 1 study in OverweightFirst studyNCT07801313 · 55 enrolled · China
- Sep 1, 2026Phase 2 study in OverweightPhase 2 reachedNCT07804810 · 120 enrolled · China
- Sep 1, 2026Phase 1 study in OverweightNCT07803809 · 36 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07804810Overweight · China | 2 | Completed | Mar 21, 2026 | 120 |
| NCT07803809Overweight · China | 1 | Recruiting | Oct 2026 | 36 |
| NCT07801313Overweight · China | 1 | Completed | Jul 20, 2025 | 55 |
How it is read
Names in the registry
- “MWN105 1”, 2 entries
- “MWN105 2”, 2 entries
- “MWN105 3”, 2 entries
- “MWN105”, 2 entries
Codes read as this program: MWN105.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.